Ocugen CFO’s hefty share‑and‑option deal sparks renewed investor buzz amid flat stock price and clinical milestone optimism.
Ocugen insider buying signals future upside: CFO’s 2027‑vesting options, clinical milestones and strong buzz suggest upcoming catalysts for the stock’s next move.
3 minutes to read